BiomX to Present Data from Phase 1b/2a Study of BX004 for the Treatment of Cystic Fibrosis Patients with Chronic Pulmonary Infections at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2024)
Abstract selected as a “Top Poster”, ranking it among the 1-2% of top-rated abstracts in the category submitted and accepted at ECCMID 2024
CAMBRIDGE, Mass. and NESS ZIONA, Israel, April 23, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and
engineered phage therapies that target specific pathogenic bacteria, today announced the Company will present data from the Phase 1b/2a study of BX004 for the treatment of cystic fibrosis patients
with chronic Pseudomonas aeruginosa pulmonary infections at ECCMID 2024, which is being held from 27-30 April 2024, in Barcelona, Spain. The abstract submitted by the Company was selected
as a “Top Poster”, ranking it among the 1-2% of top-rated abstracts in the category submitted and accepted at ECCMID 2024.
Details of the presentation:
Title: | Chronic Pseudomonas aeruginosa pulmonary infection treated with a nebulised phage cocktail in patients with cystic fibrosis: a phase 1b/2a randomised, double-blind, placebo-controlled, multicentre study |
Poster number: | P2546 |
Session type: | Poster Session |
Session title: | 5c. New or repurposed antibacterial agents: clinical studies and randomized trials |
Session date: | April 28, 2024 |
Session time/location: | 12:00-13:30 CEST in Poster Area |
Presenter: | Urania Rappo, MD, BiomX Inc., Cambridge, MA, United States |
The poster will also be made available as an ePoster for viewing by delegates on the ECCMID virtual platform during ECCMID 2024 and in the publications section of the BiomX website. | |
Lesen Sie auch
About BX004
BiomX is developing BX004, a fixed multi-phage cocktail, for the treatment of cystic fibrosis (“CF”) patients with chronic pulmonary infections caused by P. aeruginosa, a main
contributor to morbidity and mortality in patients with CF. In November 2023, BiomX announced positive topline results from Part 2 of the Phase 1b/2a trial where BX004 demonstrated improvement in
pulmonary function associated with a reduction in P. aeruginosa burden compared to placebo in a predefined subgroup of patients with reduced lung function1.